Targeting EGFR in Triple Negative Breast Cancer

被引：123

作者：

Ueno, Naoto T. ^{[1
,2
]}

Zhang, Dongwei ^{[1
,2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Breast Canc Translat Res Lab, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Morgan Welch Inflammatory Breast Canc Res Program, Houston, TX 77030 USA

来源：

JOURNAL OF CANCER | 2011年 / 2卷

关键词：

triple negative breast cancer; tyrosine kinase inhibitor; EGFR; erlotinib; metastasis; EPITHELIAL-MESENCHYMAL TRANSITION; CELLS; EXPRESSION; ERLOTINIB; COMBINATION; METASTASIS;

D O I：

10.7150/jca.2.324

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Our preliminary data show that erlotinib inhibits Triple-negative breast cancer (TNBC) in a xenograft model. However, inhibition of metastasis by erlotinib is accompanied by nonspecific effects because erlotinib can inhibit other kinases; thus, more direct targets that regulate TNBC metastasis need to be identified to improve its therapeutic efficacy.

引用

页码：324 / 328

页数：5

共 17 条

[1]

[Anonymous], MIL 35 C EUR SOC MED

[2]

[Anonymous], 2010, Certification considerations for highly-integrated or complex aircraft systems: APR 4754A

[3] NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells:: potential involvement of ZEB-1 and ZEB-2 [J].